A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMp) inhibitor reduces cancer cell motility and tumor growth

Cancer Biology and Therapy

Volumn 8, Issue 24, 2009, Pages 2362-2370

  Suojanen, Juho ^a,b   Salo, Tuula ^b   Koivunen, Erkki ^c,d   Sorsa, Timo ^a   Pirilä, Emma ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Inhibitor; Invasion; Membrane type 1 matrix metalloproteinase; Migration; MMP 14; MT1 MMP; Peptide; Tumor angiogenesis; Tumor xenograft

Indexed keywords

COLLAGENASE 3; DISULFIDE; GELATINASE A; GELATINASE B; GLYCYLALANYLCYSTEINYLPHENYLALANYLSERINYLISOLEUCYLALANYLHISTIDINYLGLUTAMYLCYSTEINYLGLYCYLALANINE; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 20; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; TONGUE CARCINOMA; TUMOR GROWTH; XENOGRAFT;

EID: 75749130283     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.24.10139     Document Type: Article

References (40)

1. Skrzydlewska E, Sulkowska M, Koda M, Sulkowski S. Proteolytic- antiproteolytic balance and its regulation in carcinogenesis. World J Gastroneterology 2005; 11:1251-66.
2. Christofori G. New signals from the invasive front. Nature 2006; 441:444-50.
3. Visse R, Nagsase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function and biochemistry. Circ Res 2003; 92:827-39.
4. Vihinen P, Kähäri VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002; 99:157-66.
5. Egelblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev Cancer 2002; 2:161-74.
6. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Met Rev 2006; 25:9-34.
7. Whittaker M, Floyd CD, Brown P, Gearing AJH. Design and therapeutic application of matrix metal-loproteinase inhibitors. Chem Rev 1999; 99:2735-76.
8. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295:2387-92.
9. Peterson JT. Matrix metalloproteinase inhibitor development and the remodelling of drug discovery. Heart Fail Rev 2004; 9:63-79.
10. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkilä P, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biot 1999; 17:768-74.
11. Heikkilä P, Suojanen J, Pirila E, Väänänen A, Koivunen E, Sorsa T, et al. Human tongue carcinoma growth is inhibited by selective antigelatinolytic peptides. Int J Cancer 2006; 118:2202-9.
12. Salo T, Sorsa T, Lindqvist C. Inhibition of gelatinase activity by cyclic peptides -a support for oral cancer treatment. Oral Oncol 2006; 42:955-6.
13. Etoh T, Inoue H, Yoshikawa Y, Barnard GF, Kitano S, Mori M. Increased expression of collagenase-3 (MMP-13) and MT1-MMP in oesophageal cancer is related to cancer aggressiveness. Gut 2000; 47:50-6.
14. Ohashi K, Nemoto T, Nakamura K, Nemori R. Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas. Cancer 2000; 88:2201-9.
15. Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett 2003; 194:1-11.
16. Heikkilä P, Teronen O, Moilanen M, Konttinen YT, Hanemaaijer R, Laitinen M, et al. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anti-Cancer Drugs 2002; 13:245-54.
17. Knight CG, Willenbrock F, Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloprotenases. FEBS Letters 1992; 296:263-6.
18. MacPherson LJ, Bayburt EK, Capparelli MP, Carroll BJ, Goldstein R, Justice MR, et al. Discovery of CGS 27023A, a non-peptidic, potent and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem 1997; 40:2525-32.
19. Pirilä E, Sharabi A, Salo T, Quaranta V, Tu H, Heljasvaara R, et al. Matrix metalloproteinase process the laminin-5 γ2-chain and regulate epithelial cell migration. Biochem Biophys Res Comm 2003; 303:1012-7.
20. Wiegand S, Dunne AA, Muller HH, Mandic R, Barth P, Davis RK, et al. Meta analysis of the significance of matrix metalloproteinases for lymph node disease in patients with head and neck squamous cell carcinoma. Cancer 2005; 104:94-100.
21. Vicente JC, Lequerica-Fernandez P, Santamaria J, Fresno MF. Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis. J Oral Pathol Med 2007; 36:415-24.
22. Fujino H, Kondo K, Ishikura H, Maki H, Kinoshita H, Miyoshi T, et al. Matrix metalloproteinase inhibitor MMI-166 inhibits lymphogenous metastasis in an orthotopically implanted model of lung cancer. Mol Cancer Ther 2005; 4:1409-16.
23. Sabeh F, Ota I, Holmbeck K, Birkedal-Hansen H, Soloway P, Balbin M, et al. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol 2004; 167:769-81.
24. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sashara RM, et al. The membrane-ancohored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001; 107:789-800.
25. Langlois S, Nyalendo C, Di Tomasso G, Labrecque L, Roghi C, Murpphy G, et al. Membrane-type 1 matrix metalloproteinase stimulates cell migration through epidermal growth factor receptor transactivation. Mol Cancer Res 2007; 5:569-83.
26. Seftor REB, Seftor EA, Kirchmann DA, Hendrix MJC. Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 γ2 chain promigratory fragments and vasculogenic mimicry. Mol Cancer Ther 2002; 1:1173-9.
27. Oku N, Sasabe E, Ueta E, Yamamoto T, Osaki T. Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 γ2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer Res 2006; 66:5251-7.
28. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, et al. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994; 370:61-5.
29. Kinoshita T, Sato H, Okada A, Ohuchi E, Imai K, Okada Y, et al. TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem 1998; 276:16098-103.
30. Nonaka T, Nishibashi K, Itoh Y, Yana I, Seiki M. Competitive distribution of the tumor-promoting function of membrane type 1 matrix metalloproteinase/ matrix metalloproteinase-14 in vivo. Mol Cancer Ther 2005; 4:1157-66.
31. Shofuda K, Moriyama K, Nishihashi A, Higashi S, Mizushima H, Yasumitsu H, et al. Role of tissue inhibitor of metallopoteinaes-(TIMP-2) in regulation of progelatinase A activation catalyzed by membrane-type matrix metalloproteinase-1 (MT1-MMP) in human cancer cells. J Biochem 1998; 124:462-70.
32. Teronen O, Heikkilä P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, et al. MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci 1999; 878:453-65.
33. Munshi HG, Wu YI, Ariztia EV, Stack SM. Calcium regulation of matrix metalloproteinase-mediated migration in oral squamous cell carcinoma cells. J Biol Chem 2002; 44:41480-8.
34. Deryugina EI, Zijlstra A, Partridge JJ, Kupriyanova TA, Madsen MA, Papagiannakopoulos T, et al. Unexpected effect of matrix metalloproteinase downregulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination. Cancer Res 2005; 65:10959-69.
35. Munoz-Najar UM, Neurath KM, Vumbaca F, Claffey KP. Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene 2006; 25:2379-92.
36. Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafia DM. Randomized phase II trial of matrix metalloproteinase inhibitior COL-3 in AIDS-related kaposi's sarcoma: an AIDS malignancy concortium study. J Clin Oncol 2006L; 24:1389-94.
37. Heath EI, Burtness BA, Kleinberg L, Salem RR, Yang SC, Heitmiller RF, et al. Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloproteinase (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Invest New Drugs 2006; 24:135-40.
38. Hudson MP, Armstrong PW, Ruzyllo W, Brum J, Cusmano L, Krzeski P, et al. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction. J Am Coll Cardiol 2006; 48:15-20.
39. Chu QSC, Forouzesh B, Syed S, Mita M, Schwartz G, Copper J, et al. A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Invest New Drugs 2007; 25:359-67.
40. Chiappori AA, Eckhardt SG, Bukowski R, Sullivan DM, Ikeda M, Yano Y, et al. A phase I pharmacokinetic and pharmacodynamic study of S-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res 2007; 13:2091-9.